Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04222972 |
| Title | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Blueprint Medicines Corporation |
| Indications | |
| Therapies |
Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Cisplatin + Pemetrexed Disodium |
| Age Groups: | senior | adult |
| Covered Countries | USA | ITA | FRA | ESP | DEU | CAN | BEL |
CKB BOOST